EMPAGLIFLOZIN

Jardiance 10 mg once daily and requiring additional glycaemic control, the dose can be increased to
25 mg once daily.

Action Empagliflozin is a reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2), the main

site of filtered glucose reabsorption in the renal proximal convoluted tubules. This reduces
reabsorption of filtered glucose and lowers renal threshold for glucose, resulting in
increased urinary glucose excretion, thereby reducing blood glucose concentration.

Absorption Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1.5
hours.

Distribution Volume of distribution: 73.8 L. Plasma protein binding: 86.2%.

Excretion Via urine (54.4%, 50% as unchanged drug); faeces (41.2%, mainly as unchanged drug).
Elimination half-life: 12.4 hours.

Indications and Type 2 diabetes mellitus

Dosage
Adult: As monotherapy or in combination with other antidiabetic agents: Initially, 10 mg
once daily, may be increased to 25 mg daily if necessary.

Elderly: ≥85 years Not recommended.

eGFR <60 Do not initiate therapy or reduce to 10 mg daily in patients already taking empagliflozin.
mL/min/1.73 m2

eGFR <45 Contraindicated

mL/min/1.73 m2,
ESRD, patient on
dialysis

Jardiance Duo Empagliflozin + Metformin

GFR ≥90 mL/min maximum recommended daily dose of Empagliflozin + Metformin HCl (JARDIANCE DUO) is
25 mg of empagliflozin and 2000 mg of metformin
Glyxambi Empagliflozin + Linagliptin

Initially 10 mg/5 mg once daily, may be increased to 25 mg/5 mg once daily for patients requiring additional
glycemic control.

No dose adjustment is required for patients with eGFR ≥30 mL/min/1.73 m2.

Empagliflozin + Linagliptin (GLYXAMBI) is not recommended for use in patients with eGFR <30 mL/min/1.73 m2